Home > Insider Trading > Filing (0001567619-18-004867)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1382911	Orexigen Therapeutics Inc.	OREXQ	()	MA

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
899869	A Seth Klarman	10 St. James Avenue Suite 1700 Boston MA 02116	No	No	Yes	No
1061768	Baupost Group Llc/Ma	10 St. James Avenue Suite 1700 Boston MA 02116	No	No	Yes	No
1738693	Baupost Group Gp, L.l.c.	10 St. James Avenue Suite 1700 Boston MA 02116	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2018-10-29	650,000	$0.01	896,339	No	4	S	Indirect	See footnote 1 and 2
Common Stock	Disposition	2018-10-31	896,339	$0.01	0	No	4	S	Indirect	See footnote 1 and 2

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See footnote 1 and 2
No	4	S	Indirect	See footnote 1 and 2

Footnotes

This statement on Form 4 is being jointly filed by The Baupost Group, L.L.C. ("Baupost"), Baupost Group GP, L.L.C. ("BG GP"), and Seth A. Klarman (collectively, the "Reporting Persons"). Baupost is a registered investment adviser and acts as an investment adviser to various private investment limited partnerships. BG GP, as the Manager of Baupost, and Seth A. Klarman, as the Managing Member of BG GP and a controlling person of Baupost, may be deemed to have beneficial ownership under Section 13 of the Securities Exchange Act of 1934, as amended, of the securities beneficially owned by Baupost. Securities reported on this Form 4 as being beneficially owned by Baupost were purchased on behalf of certain of such partnerships.
(Continued from footnote 1) The Reporting Persons disclaim beneficial ownership of the securities indicated except to the extent of their pecuniary therein, and the reporting herein of such securities shall not be construed as an admission that the Reporting Persons are the beneficial owners thereof for purpose of Section 16 or for any otherpurpose.